Evidence map›Paper›PMID 40731030›Full record

ArticleGenes and environment : the official journal of the Japanese Environmental Mutagen Society2025

Whole genome mutagenicity evaluation using Hawk-Seq™ demonstrates high inter-laboratory reproducibility and concordance with the transgenic rodent gene mutation assay.

Shoji Matsumura, Sayaka Hosoi, Takako Hirose, Yuki Otsubo, Kazutoshi Saito, Masaaki Miyazawa, Akihiro Kawade, Atsushi Hakura, Dai Kakiuchi, Shoji Asakura and 7 more

Abstract read
In one paragraph

Article in Genes and environment : the official journal of the Japanese Environmental Mutagen Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Complex versus simpleScience advances · 2026
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Shoji MatsumuraR&D -Safety Science Research, Kao Corporation, 3-25-14 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa, 210-0821, Japan. matsumura.shouji@kao.com.
Sayaka HosoiR&D -Safety Science Research, Kao Corporation, 3-25-14 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa, 210-0821, Japan.
Takako HiroseR&D -Safety Science Research, Kao Corporation, 3-25-14 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa, 210-0821, Japan.
Yuki OtsuboR&D -Safety Science Research, Kao Corporation, 3-25-14 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa, 210-0821, Japan.
Kazutoshi SaitoR&D -Safety Science Research, Kao Corporation, 2606 Akabane, Ichikai-Machi, Haga-Gun, Tochigi, 321-3497, Japan.
Masaaki MiyazawaR&D -Safety Science Research, Kao Corporation, 2606 Akabane, Ichikai-Machi, Haga-Gun, Tochigi, 321-3497, Japan.
Akihiro KawadeDrug Safety & Animal Care Technology Unit, Tsukuba Division, Sunplanet Co., Ltd, 5-1-3 Tokodai, Tsukuba-shi, Ibaraki, 300-2635, Japan.
Atsushi HakuraDrug Safety & Animal Care Technology Unit, Tsukuba Division, Sunplanet Co., Ltd, 5-1-3 Tokodai, Tsukuba-shi, Ibaraki, 300-2635, Japan.
Dai KakiuchiGlobal Drug Safety, Eisai Co., Ltd, 5-1-3 Tokodai, Tsukuba-shi, Ibaraki, 300-2635, Japan.
Shoji AsakuraGlobal Drug Safety, Eisai Co., Ltd, 5-1-3 Tokodai, Tsukuba-shi, Ibaraki, 300-2635, Japan.
Naoki KoyamaTranslational Research Division, Safety and Bioscience Research Department, Chugai Pharmaceutical Co., Ltd, 216 Totsuka, Totsuka-ku, Yokohama-shi, Kanagawa, 244- 8602, Japan.
Yuki OkadaTeijin Pharma Limited, 4-3-2 Asahigaoka, Hino, Tokyo, 191-8512, Japan.
Satsuki ChikuraTeijin Pharma Limited, 4-3-2 Asahigaoka, Hino, Tokyo, 191-8512, Japan.
Takafumi KimotoTeijin Pharma Limited, 4-3-2 Asahigaoka, Hino, Tokyo, 191-8512, Japan.
Kenichi MasumuraDivision of Risk Assessment, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa, 210-9501, Japan.
Takayoshi SuzukiDivision of Genome Safety Science, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa, 210-9501, Japan.
Kei-Ichi SugiyamaDivision of Genome Safety Science, National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa, 210-9501, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundError-corrected next-generation sequencing (ecNGS) enables the sensitive detection of chemically induced mutations. Matsumura et al. reported Hawk-Seq™, an ecNGS method, demonstrating its utility in clarifying mutagenicity both qualitatively and quantitatively. To further promote the adoption of ecNGS-based assays, it is important to evaluate their inter-laboratory transferability and reproducibility. Therefore, we evaluated the inter-laboratory reproducibility of Hawk-Seq™ and its concordance with the transgenic rodent mutation (TGR) assay.

resultsThe Hawk-Seq™ protocol was successfully transferred from the developer's laboratory (lab A) to two additional laboratories (labs B, C). Whole genomic mutations were analyzed independently using the same genomic DNA samples from the livers of gpt delta mice exposed to benzo[a]pyrene (BP), N-ethyl-N-nitrosourea (ENU), and N-methyl-N-nitrosourea (MNU). In all laboratories, clear dose-dependent increases in base substitution (BS) frequencies were observed, specific to each mutagen (e.g. G:C to T:A for BP). Statistically significant increases in overall mutation frequencies (OMFs) were identified at the same doses across all laboratories, suggesting high reproducibility in mutagenicity assessment. The correlation coefficient (r

conclusionsHawk-Seq™-based whole-genome mutagenicity evaluation demonstrated high inter-laboratory reproducibility and concordance with gpt assay results. Our results contribute to the growing evidence that ecNGS assays provide a suitable, or improved, alternative to the TGR assay.

Indexed as

Error-corrected next-generation sequencingHawk-Seq™Mutagenicity assayReproducibilityTransferabilityTransgenic rodent modelValidation study

Identifiers

PMID40731030
PMCPMC12305950

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.